RU2006107578A - 6-арилпиримидин, применяемый в качестве противоракового агента - Google Patents
6-арилпиримидин, применяемый в качестве противоракового агента Download PDFInfo
- Publication number
- RU2006107578A RU2006107578A RU2006107578/04A RU2006107578A RU2006107578A RU 2006107578 A RU2006107578 A RU 2006107578A RU 2006107578/04 A RU2006107578/04 A RU 2006107578/04A RU 2006107578 A RU2006107578 A RU 2006107578A RU 2006107578 A RU2006107578 A RU 2006107578A
- Authority
- RU
- Russia
- Prior art keywords
- chloro
- carbon atoms
- amine
- pyrimidin
- pharmaceutically acceptable
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 67
- 150000003839 salts Chemical class 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 33
- -1 phenoxy, benzyl Chemical group 0.000 claims 29
- 238000000034 method Methods 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 229910052794 bromium Inorganic materials 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 8
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102000004243 Tubulin Human genes 0.000 claims 6
- 108090000704 Tubulin Proteins 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 6
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 230000036457 multidrug resistance Effects 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 102000029749 Microtubule Human genes 0.000 claims 3
- 108091022875 Microtubule Proteins 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 210000004688 microtubule Anatomy 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- USCQBKSUWCKHKG-UHFFFAOYSA-N 2-(5-azidopyridin-2-yl)-6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC(=CC=2)N=[N+]=[N-])N=C1NCC(F)(F)F USCQBKSUWCKHKG-UHFFFAOYSA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- VKAOCYPNKOPRSE-UHFFFAOYSA-N 3-[4-(4-chloro-6-cycloheptyl-2-pyrazin-2-ylpyrimidin-5-yl)-3,5-difluorophenoxy]-n-methylpropan-1-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1C1CCCCCC1 VKAOCYPNKOPRSE-UHFFFAOYSA-N 0.000 claims 2
- CBWLEMXYPINBTA-UHFFFAOYSA-N 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-pyrazin-2-yl-n-(1,1,1-trifluoropropan-2-yl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1NC(C)C(F)(F)F CBWLEMXYPINBTA-UHFFFAOYSA-N 0.000 claims 2
- CBWLEMXYPINBTA-LLVKDONJSA-N 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-pyrazin-2-yl-n-[(2r)-1,1,1-trifluoropropan-2-yl]pyrimidin-4-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1N[C@H](C)C(F)(F)F CBWLEMXYPINBTA-LLVKDONJSA-N 0.000 claims 2
- CBWLEMXYPINBTA-NSHDSACASA-N 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-pyrazin-2-yl-n-[(2s)-1,1,1-trifluoropropan-2-yl]pyrimidin-4-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1N[C@@H](C)C(F)(F)F CBWLEMXYPINBTA-NSHDSACASA-N 0.000 claims 2
- SXRPINFLPQMOJG-GFCCVEGCSA-N 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-pyridin-2-yl-n-[(2r)-1,1,1-trifluoropropan-2-yl]pyrimidin-4-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=CC=2)N=C1N[C@H](C)C(F)(F)F SXRPINFLPQMOJG-GFCCVEGCSA-N 0.000 claims 2
- SXRPINFLPQMOJG-LBPRGKRZSA-N 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-pyridin-2-yl-n-[(2s)-1,1,1-trifluoropropan-2-yl]pyrimidin-4-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=CC=2)N=C1N[C@@H](C)C(F)(F)F SXRPINFLPQMOJG-LBPRGKRZSA-N 0.000 claims 2
- HXJHMTCVYUBCGI-UHFFFAOYSA-N 6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-2-pyrazin-2-yl-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1NCC(F)(F)F HXJHMTCVYUBCGI-UHFFFAOYSA-N 0.000 claims 2
- CMRXBBZWPSTMEC-UHFFFAOYSA-N 6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-2-pyrimidin-2-yl-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=CN=2)N=C1NCC(F)(F)F CMRXBBZWPSTMEC-UHFFFAOYSA-N 0.000 claims 2
- DDOWVXUYVOTAEQ-UHFFFAOYSA-N 6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-2-quinolin-2-yl-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(C=2N=C3C=CC=CC3=CC=2)N=C1NCC(F)(F)F DDOWVXUYVOTAEQ-UHFFFAOYSA-N 0.000 claims 2
- NAYVKTCBVLDANS-UHFFFAOYSA-N CN(C)CCOC(C=C1F)=CC(F)=C1C1=C(NCC(F)(F)F)N=C(CNC#N)N=C1Cl Chemical compound CN(C)CCOC(C=C1F)=CC(F)=C1C1=C(NCC(F)(F)F)N=C(CNC#N)N=C1Cl NAYVKTCBVLDANS-UHFFFAOYSA-N 0.000 claims 2
- XCWLPLOUCMTHFI-UHFFFAOYSA-N [4-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-6-(1,1,1-trifluoropropan-2-ylamino)pyrimidin-2-yl]methylcyanamide Chemical compound FC(F)(F)C(C)NC1=NC(CNC#N)=NC(Cl)=C1C1=C(F)C=C(OCCCN(C)C)C=C1F XCWLPLOUCMTHFI-UHFFFAOYSA-N 0.000 claims 2
- ZXUDPCQCQFLPJR-UHFFFAOYSA-N [4-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-6-(2,2,2-trifluoroethylamino)pyrimidin-2-yl]-methylcyanamide Chemical compound FC1=CC(OCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(N(C)C#N)N=C1NCC(F)(F)F ZXUDPCQCQFLPJR-UHFFFAOYSA-N 0.000 claims 2
- CKWQLHOKWJDKEX-NSHDSACASA-N [4-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-6-[[(2s)-1,1,1-trifluoropropan-2-yl]amino]pyrimidin-2-yl]-methylcyanamide Chemical compound FC(F)(F)[C@H](C)NC1=NC(N(C)C#N)=NC(Cl)=C1C1=C(F)C=C(OCCCN(C)C)C=C1F CKWQLHOKWJDKEX-NSHDSACASA-N 0.000 claims 2
- MQQNODRQFDMVEW-UHFFFAOYSA-N [4-chloro-5-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-6-(2,2,2-trifluoroethylamino)pyrimidin-2-yl]-methylcyanamide Chemical compound FC1=CC(OCCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(N(C)C#N)N=C1NCC(F)(F)F MQQNODRQFDMVEW-UHFFFAOYSA-N 0.000 claims 2
- 239000000010 aprotic solvent Substances 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- FGDWZLMPZYDLKE-UHFFFAOYSA-N 6-chloro-2-(1-methylimidazol-2-yl)-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound CN1C=CN=C1C1=NC(Cl)=C(C=2C(=CC(F)=CC=2F)F)C(NCC(F)(F)F)=N1 FGDWZLMPZYDLKE-UHFFFAOYSA-N 0.000 claims 1
- AAVPJMAUGKOJNP-UHFFFAOYSA-N 6-chloro-2-(1h-pyrrol-2-yl)-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2NC=CC=2)N=C1NCC(F)(F)F AAVPJMAUGKOJNP-UHFFFAOYSA-N 0.000 claims 1
- ADGOHMZGCSFAOQ-UHFFFAOYSA-N 6-chloro-2-(4-methylpyridin-2-yl)-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound CC1=CC=NC(C=2N=C(NCC(F)(F)F)C(=C(Cl)N=2)C=2C(=CC(F)=CC=2F)F)=C1 ADGOHMZGCSFAOQ-UHFFFAOYSA-N 0.000 claims 1
- LNCPZOZLBVKFPW-UHFFFAOYSA-N 6-chloro-2-(5-nitropyridin-2-yl)-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound N1=CC([N+](=O)[O-])=CC=C1C1=NC(Cl)=C(C=2C(=CC(F)=CC=2F)F)C(NCC(F)(F)F)=N1 LNCPZOZLBVKFPW-UHFFFAOYSA-N 0.000 claims 1
- LILWNAIAPCBLHU-UHFFFAOYSA-N 6-chloro-2-imidazol-1-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(N2C=NC=C2)N=C1NCC(F)(F)F LILWNAIAPCBLHU-UHFFFAOYSA-N 0.000 claims 1
- QBYHZMDVKBPHAA-UHFFFAOYSA-N 6-chloro-2-isoquinolin-1-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2C3=CC=CC=C3C=CN=2)N=C1NCC(F)(F)F QBYHZMDVKBPHAA-UHFFFAOYSA-N 0.000 claims 1
- GNJIOXWXWUUCQZ-UHFFFAOYSA-N 6-chloro-2-isoquinolin-3-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC3=CC=CC=C3C=2)N=C1NCC(F)(F)F GNJIOXWXWUUCQZ-UHFFFAOYSA-N 0.000 claims 1
- USZDFOPAUAEWBC-ZETCQYMHSA-N 6-chloro-2-pyrazin-2-yl-5-(2,4,6-trifluorophenyl)-n-[(2s)-1,1,1-trifluoropropan-2-yl]pyrimidin-4-amine Chemical compound FC(F)(F)[C@H](C)NC1=NC(C=2N=CC=NC=2)=NC(Cl)=C1C1=C(F)C=C(F)C=C1F USZDFOPAUAEWBC-ZETCQYMHSA-N 0.000 claims 1
- RFSSBTBRSZAIBG-UHFFFAOYSA-N 6-chloro-2-pyrazin-2-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1NCC(F)(F)F RFSSBTBRSZAIBG-UHFFFAOYSA-N 0.000 claims 1
- PYOACZADEZQCJS-UHFFFAOYSA-N 6-chloro-2-pyridin-2-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=CC=2)N=C1NCC(F)(F)F PYOACZADEZQCJS-UHFFFAOYSA-N 0.000 claims 1
- ODKBOKAYDWNIFV-UHFFFAOYSA-N 6-chloro-2-pyridin-3-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2C=NC=CC=2)N=C1NCC(F)(F)F ODKBOKAYDWNIFV-UHFFFAOYSA-N 0.000 claims 1
- IOOKTIUCSYUVRN-UHFFFAOYSA-N 6-chloro-2-pyridin-4-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2C=CN=CC=2)N=C1NCC(F)(F)F IOOKTIUCSYUVRN-UHFFFAOYSA-N 0.000 claims 1
- YDUXGZDCHMEEGU-UHFFFAOYSA-N 6-chloro-2-pyrrol-1-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(N2C=CC=C2)N=C1NCC(F)(F)F YDUXGZDCHMEEGU-UHFFFAOYSA-N 0.000 claims 1
- ZDOGRDYQRDOYPT-UHFFFAOYSA-N 6-chloro-2-quinolin-2-yl-n-(2,2,2-trifluoroethyl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N=C(C=2N=C3C=CC=CC3=CC=2)N=C1NCC(F)(F)F ZDOGRDYQRDOYPT-UHFFFAOYSA-N 0.000 claims 1
- SXRPINFLPQMOJG-UHFFFAOYSA-N 6-chloro-5-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-2-pyridin-2-yl-n-(1,1,1-trifluoropropan-2-yl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=CC=2)N=C1NC(C)C(F)(F)F SXRPINFLPQMOJG-UHFFFAOYSA-N 0.000 claims 1
- LDESLYKWJNFLSX-UHFFFAOYSA-N 6-chloro-5-[4-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-2-pyrazin-2-yl-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1NCC(F)(F)F LDESLYKWJNFLSX-UHFFFAOYSA-N 0.000 claims 1
- QIHITHOIUNZULD-UHFFFAOYSA-N 6-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-2-imidazol-1-yl-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(N2C=NC=C2)N=C1NCC(F)(F)F QIHITHOIUNZULD-UHFFFAOYSA-N 0.000 claims 1
- ZIHOWUDDUIKPMZ-UHFFFAOYSA-N 6-chloro-5-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-2-pyrazin-2-yl-n-(2,2,2-trifluoroethyl)pyrimidin-4-amine Chemical compound FC1=CC(OCCCCN(C)C)=CC(F)=C1C1=C(Cl)N=C(C=2N=CC=NC=2)N=C1NCC(F)(F)F ZIHOWUDDUIKPMZ-UHFFFAOYSA-N 0.000 claims 1
- DSHRUPCKUSKOTO-UHFFFAOYSA-N CC1(N)NC=CC(NCC(F)(F)F)=N1 Chemical compound CC1(N)NC=CC(NCC(F)(F)F)=N1 DSHRUPCKUSKOTO-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- CKWQLHOKWJDKEX-LLVKDONJSA-N [4-chloro-5-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-6-[[(2r)-1,1,1-trifluoropropan-2-yl]amino]pyrimidin-2-yl]-methylcyanamide Chemical compound FC(F)(F)[C@@H](C)NC1=NC(N(C)C#N)=NC(Cl)=C1C1=C(F)C=C(OCCCN(C)C)C=C1F CKWQLHOKWJDKEX-LLVKDONJSA-N 0.000 claims 1
- ODURFEQFDLNVNA-UHFFFAOYSA-N [4-chloro-6-(2,2,2-trifluoroethylamino)-5-(2,4,6-trifluorophenyl)pyrimidin-2-yl]-methylcyanamide Chemical compound FC(F)(F)CNC1=NC(N(C#N)C)=NC(Cl)=C1C1=C(F)C=C(F)C=C1F ODURFEQFDLNVNA-UHFFFAOYSA-N 0.000 claims 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 1
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims 1
- 150000008046 alkali metal hydrides Chemical class 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- JOGZZTFIGKYTSV-UHFFFAOYSA-N ethylcyanamide Chemical compound CCNC#N JOGZZTFIGKYTSV-UHFFFAOYSA-N 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- MCLITRXWHZUNCQ-UHFFFAOYSA-N methylcyanamide Chemical compound CNC#N MCLITRXWHZUNCQ-UHFFFAOYSA-N 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50548703P | 2003-09-24 | 2003-09-24 | |
| US60/505,487 | 2003-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006107578A true RU2006107578A (ru) | 2007-10-27 |
Family
ID=34393022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006107578/04A RU2006107578A (ru) | 2003-09-24 | 2004-09-17 | 6-арилпиримидин, применяемый в качестве противоракового агента |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7524849B2 (https=) |
| EP (1) | EP1663241B1 (https=) |
| JP (1) | JP2007506746A (https=) |
| KR (1) | KR20060089215A (https=) |
| CN (1) | CN1871009A (https=) |
| AR (1) | AR045811A1 (https=) |
| AT (1) | ATE432077T1 (https=) |
| AU (1) | AU2004275733A1 (https=) |
| BR (1) | BRPI0414736A (https=) |
| CA (1) | CA2539235A1 (https=) |
| CO (1) | CO5690592A2 (https=) |
| DE (1) | DE602004021269D1 (https=) |
| EC (1) | ECSP066457A (https=) |
| GT (1) | GT200400188A (https=) |
| IL (1) | IL174305A0 (https=) |
| MX (1) | MXPA06003207A (https=) |
| NO (1) | NO20061319L (https=) |
| PA (1) | PA8613201A1 (https=) |
| PE (1) | PE20050470A1 (https=) |
| RU (1) | RU2006107578A (https=) |
| SA (1) | SA04250303A (https=) |
| TW (1) | TW200512198A (https=) |
| WO (1) | WO2005030216A1 (https=) |
| ZA (1) | ZA200602386B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
| MX2007015718A (es) * | 2005-06-13 | 2008-02-21 | Wyeth Corp | Inhibidor de tubulina y proceso para su preparacion. |
| CN101193884A (zh) | 2005-06-13 | 2008-06-04 | 惠氏公司 | 微管蛋白抑制剂和其制备方法 |
| WO2007110418A2 (de) * | 2006-03-27 | 2007-10-04 | Basf Se | Substituierte 5-hetaryl-4-aminopyrimidine |
| CL2007002231A1 (es) * | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
| TW200836741A (en) * | 2007-01-11 | 2008-09-16 | Basf Ag | 2-substituted pyrimidines I in therapy |
| WO2009007187A1 (de) * | 2007-07-09 | 2009-01-15 | Basf Se | Substituierte 5-hetarylpyrimidine |
| US9139534B2 (en) | 2011-04-22 | 2015-09-22 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| US9649317B2 (en) | 2012-09-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| CN107108524A (zh) | 2014-12-16 | 2017-08-29 | 西格诺药品有限公司 | 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物 |
| US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN107922287B (zh) | 2015-07-24 | 2021-04-09 | 细胞基因公司 | 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体 |
| US11623927B2 (en) | 2018-03-02 | 2023-04-11 | The Trustees Of The University Of Pennsylvania | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules |
| EP4052759A4 (en) * | 2019-11-01 | 2023-12-20 | Unimatec Co., Ltd. | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF |
| TW202132285A (zh) * | 2019-11-13 | 2021-09-01 | 美商愛彼特生物製藥股份有限公司 | 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US116429A (en) * | 1871-06-27 | Improvement in dial-telegraph apparatus | ||
| US61889A (en) * | 1867-02-05 | Improvement in animal teaps | ||
| US69242A (en) * | 1867-09-24 | Calvin pepper | ||
| US88096A (en) * | 1869-03-23 | t h a y e r | ||
| US147744A (en) * | 1874-02-24 | Improvement in locomotive-furnaces | ||
| GB9700664D0 (en) | 1997-01-14 | 1997-03-05 | British Tech Group | Anti-cancer agents |
| US6117876A (en) * | 1997-04-14 | 2000-09-12 | American Cyanamid Company | Fungicidal trifluorophenyl-triazolopyrimidines |
| DE69934224T2 (de) | 1998-04-27 | 2007-10-04 | Kumiai Chemical Industry Co., Ltd. | 3-arylphenylsulfid-derivate und insektizide und mitizide |
| US6156925A (en) * | 1998-09-25 | 2000-12-05 | American Cyanamid Company | Process for the preparation of halogenated phenylmaloates |
| US5986135A (en) * | 1998-09-25 | 1999-11-16 | American Cyanamid Company | Fungicidal trifluoromethylalkylamino-triazolopyrimidines |
| JP2004503542A (ja) * | 2000-06-13 | 2004-02-05 | ビーエーエスエフ アクチェンゲゼルシャフト | 殺真菌性５−フェニル置換２−（シアノアミノ）ピリミジン誘導体 |
| US6670362B2 (en) * | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
| EA007719B1 (ru) * | 2001-03-15 | 2006-12-29 | Басф Акциенгезельшафт | 5-фенилпиримидины, способ и промежуточные продукты для их получения и их применение для борьбы с фитопатогенными грибами |
| ES2242839T3 (es) * | 2001-04-20 | 2005-11-16 | Ciba Specialty Chemicals Holding Inc. | 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas. |
| NZ533265A (en) | 2001-11-19 | 2006-05-26 | Basf Ag | 5-Phenylpyrimidines, their preparation, compositions comprising them and their use |
| US7320975B2 (en) | 2002-02-21 | 2008-01-22 | Basf Aktiengesellschaft | 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi |
| US7731985B2 (en) | 2002-03-15 | 2010-06-08 | Ciba Specialty Chemicals Corporation | 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces |
| EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
-
2004
- 2004-09-17 RU RU2006107578/04A patent/RU2006107578A/ru not_active Application Discontinuation
- 2004-09-17 AT AT04784529T patent/ATE432077T1/de not_active IP Right Cessation
- 2004-09-17 CA CA002539235A patent/CA2539235A1/en not_active Abandoned
- 2004-09-17 EP EP04784529A patent/EP1663241B1/en not_active Expired - Lifetime
- 2004-09-17 BR BRPI0414736-7A patent/BRPI0414736A/pt not_active IP Right Cessation
- 2004-09-17 KR KR1020067005903A patent/KR20060089215A/ko not_active Withdrawn
- 2004-09-17 WO PCT/US2004/030682 patent/WO2005030216A1/en not_active Ceased
- 2004-09-17 AU AU2004275733A patent/AU2004275733A1/en not_active Withdrawn
- 2004-09-17 DE DE602004021269T patent/DE602004021269D1/de not_active Expired - Fee Related
- 2004-09-17 JP JP2006528086A patent/JP2007506746A/ja not_active Withdrawn
- 2004-09-17 MX MXPA06003207A patent/MXPA06003207A/es unknown
- 2004-09-17 CN CNA200480031581XA patent/CN1871009A/zh active Pending
- 2004-09-21 TW TW093128501A patent/TW200512198A/zh unknown
- 2004-09-22 SA SA04250303A patent/SA04250303A/ar unknown
- 2004-09-22 PE PE2004000922A patent/PE20050470A1/es not_active Application Discontinuation
- 2004-09-23 AR ARP040103441A patent/AR045811A1/es not_active Application Discontinuation
- 2004-09-23 GT GT200400188A patent/GT200400188A/es unknown
- 2004-09-24 PA PA20048613201A patent/PA8613201A1/es unknown
- 2004-09-24 US US10/950,375 patent/US7524849B2/en not_active Expired - Fee Related
-
2006
- 2006-03-13 IL IL174305A patent/IL174305A0/en unknown
- 2006-03-23 NO NO20061319A patent/NO20061319L/no not_active Application Discontinuation
- 2006-03-23 ZA ZA200602386A patent/ZA200602386B/xx unknown
- 2006-03-24 EC EC2006006457A patent/ECSP066457A/es unknown
- 2006-04-21 CO CO06038135A patent/CO5690592A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20061319L (no) | 2006-04-20 |
| EP1663241B1 (en) | 2009-05-27 |
| JP2007506746A (ja) | 2007-03-22 |
| GT200400188A (es) | 2005-05-02 |
| KR20060089215A (ko) | 2006-08-08 |
| DE602004021269D1 (de) | 2009-07-09 |
| PA8613201A1 (es) | 2005-11-25 |
| AU2004275733A1 (en) | 2005-04-07 |
| SA04250303A (ar) | 2005-12-03 |
| US20050075357A1 (en) | 2005-04-07 |
| MXPA06003207A (es) | 2006-06-23 |
| AR045811A1 (es) | 2005-11-16 |
| CA2539235A1 (en) | 2005-04-07 |
| US7524849B2 (en) | 2009-04-28 |
| CN1871009A (zh) | 2006-11-29 |
| TW200512198A (en) | 2005-04-01 |
| ZA200602386B (en) | 2009-03-25 |
| BRPI0414736A (pt) | 2006-11-21 |
| IL174305A0 (en) | 2008-02-09 |
| ECSP066457A (es) | 2006-09-18 |
| ATE432077T1 (de) | 2009-06-15 |
| EP1663241A1 (en) | 2006-06-07 |
| PE20050470A1 (es) | 2005-10-03 |
| CO5690592A2 (es) | 2006-10-31 |
| WO2005030216A1 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006107578A (ru) | 6-арилпиримидин, применяемый в качестве противоракового агента | |
| EP3205650B1 (en) | Egfr inhibitor, and preparation and application thereof | |
| CN105461695B (zh) | 嘧啶或三嗪衍生物及其制备方法和用途 | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| JP2007506746A5 (https=) | ||
| ES2759480T3 (es) | Nuevos derivados de hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CN104125957B (zh) | 取代的苄基吡唑 | |
| CA2997039C (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| JP2022536540A5 (https=) | ||
| WO2015015318A4 (en) | Novel quinazolinones as bromodomain inhibitors | |
| WO2013026914A1 (en) | Serine/threonine pak1 inhibitors | |
| EP3356364A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
| JP2006502235A5 (https=) | ||
| AU2013305634A1 (en) | Novel 4,6-disubstituted aminopyrimidine derivatives | |
| KR20170005875A (ko) | 1,3,4-티아디아졸 화합물 및 암의 치료에서의 그의 용도 | |
| TWI334868B (en) | [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof | |
| AU2018337138B2 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
| CA2479363A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
| AU2010315361B2 (en) | Quinazoline compounds | |
| RU2006107579A (ru) | 6-[(замещенный)фенил]триазолопиримидины в качестве противораковых препаратов | |
| IL291958A (en) | 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
| KR20220125279A (ko) | Ｅｇｆｒ/ｈｅｒ２의 시아노-피리미딘 억제제 | |
| CN103476769B (zh) | 抗癌剂 | |
| CN104995179A (zh) | 作为hcv抗病毒剂的n-杂芳基取代的苯胺衍生物 | |
| WO2020002968A1 (en) | Triazolotriazine derivatives as a2a receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080416 |